PCM
VKTX icon

Prelude Capital Management’s Viking Therapeutics VKTX Stock Holding History

Prelude Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$820K – 1516
2024
Q1 		$820K Buy
+10,000
New +$445K 0.04% 451
2020
Q3 		– Sell
-200
Closed -$1K – 2391
2020
Q2 		$1K Buy
+200
New +$1.33K ﹤0.01% 1892

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Prelude Capital Management's VKTX Position: Q2 2026 in Review

Prelude Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 15,051 shares — an estimated $490K sold.

Prelude Capital Management first reported a position in VKTX in Q2 2018 and held it in 8 quarters. The position peaked at $2.16M in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Prelude Capital Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 15,051 Viking Therapeutics shares in Q2 2026, an estimated $490K.
  • Prelude Capital Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 8 quarters.
  • Prelude Capital Management's Viking Therapeutics position peaked at $2.16M in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.